Roche is handing over $595 million to bolster its Foundation Medicine business with a deal to snap up SAGA Diagnostics. Through the deal, the Swiss major gets it hands on Saga’s Pathlight, a personalized, tumor-informed molecular residual disease (MRD) platform. This platform uses structural variant biology, enabling it to be ultra-sensitive in picking up a range of cancers. Saga has already commercialized the platform in early breast cancer, as well as colorectal cancer. The company has previously guided to a sales target of around $150 million in 2028 sales.
Read the full article: Roche Boosts Diagnostics Offerings with $595M Saga Buyout //
Source: https://www.fiercebiotech.com/medtech/roche-boosts-diagnostics-offering-595m-saga-buyout